A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.
Pancreatic Cancer|Advanced Pancreatic Cancer|Pancreatic Adenocarcinoma|Pancreatic Neoplasms
DRUG: anti-EGFR-bispecific antibody armed activated T-cells
Evaluate toxicity, The NCI CTEP CTCAE v4.0 will be used., 1 year
The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.